Peanut‐induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry
Allergy2020Vol. 76(5), pp. 1517–1527
Citations Over TimeTop 10% of 2020 papers
Ioana Maris, Sabine Dölle, Jean‐Marie Renaudin, Lars Lange, Alice Koehli, Thomas Spindler, Jonathan O’B Hourihane, Kathrin Scherer, Katja Nemat, Christoph Kemen, Irena Neustädter, Christian Vogelberg, Thomas S. Reese, İsmail Yıldız, Zsolt Szépfalusi, Hagen Ott, Helen Straube, Nikolaos G. Papadopoulos, Susanne Hämmerling, U. Staden, M Polz, Tihomir B. Mustakov, Ewa Cichocka‐Jarosz, Renata Rodrigues Cocco, Alessandro Fiocchi, Montserrat Fernández‐Rivas, Margitta Worm, Network for Online Registration of Anaphylaxis (NORA)
Abstract
The European Anaphylaxis Registry data confirmed peanut as one of the major causes of severe, potentially life-threatening allergic reactions in European children, with some characteristic features e.g., presence of asthma comorbidity and increased rate of biphasic reactions. Usage of intramuscular adrenaline as first-line treatment is low and needs to be improved. The Registry, designed as the largest database on anaphylaxis, allows continuous assessment of this condition.
Related Papers
- → Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities(2018)117 cited
- → Who Needs Epinephrine? Anaphylaxis, Autoinjectors, and Parachutes(2023)37 cited
- → Epinephrine (Adrenaline) in Anaphylaxis(2010)19 cited
- → Pediatrician perspectives on symptom presentation and treatment of acute allergic reactions(2020)10 cited
- → 363: COMPARING EPINEPHRINE 0.3 MG AND 0.5 MG AS AN INITIAL DOSE IN COMPLETE RESOLUTION OF ANAPHYLAXIS(2022)